Vanguard Global Advisers’s ADC Therapeutics ADCT Stock Holding History
Bought
Maintained
Sold
Other funds holding ADCT
ACM
OM
Vanguard Global Advisers's ADCT Position: Q3 2026 in Review
Vanguard Global Advisers opened a new position in ADC Therapeutics (ADCT) in Q3 2026: 635 shares worth $775. The stake represents ﹤0.01% of the portfolio and ranks #3703 among its holdings. This is a return to the name: Vanguard Global Advisers previously reported a position in ADCT as recently as Q1 2026.
Vanguard Global Advisers first reported a position in ADCT in Q1 2026 and has held it in 2 quarters since. The position peaked at $118K in Q1 2026. 110 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.
- Vanguard Global Advisers held 635 shares of ADC Therapeutics worth $775 as of Q3 2026.
- ADC Therapeutics was a new Vanguard Global Advisers position in Q3 2026.
- ADC Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3703 holding.
- Vanguard Global Advisers first reported a position in ADC Therapeutics in Q1 2026 and has held it in 2 quarters since.
- Vanguard Global Advisers's ADC Therapeutics position peaked at $118K in Q1 2026.
- 110 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.